First Bank & Trust Cuts Stake in Sanofi (NASDAQ:SNY)

First Bank & Trust cut its stake in Sanofi (NASDAQ:SNY) by 3.9% during the 4th quarter, HoldingsChannel reports. The firm owned 56,964 shares of the company’s stock after selling 2,303 shares during the quarter. First Bank & Trust’s holdings in Sanofi were worth $2,747,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Northwest Investment Counselors LLC purchased a new position in Sanofi in the third quarter valued at about $29,000. Synergy Asset Management LLC purchased a new position in Sanofi in the fourth quarter valued at about $25,000. Concord Wealth Partners raised its position in Sanofi by 157.8% in the third quarter. Concord Wealth Partners now owns 593 shares of the company’s stock valued at $34,000 after purchasing an additional 363 shares during the period. McClarren Financial Advisors Inc. raised its position in Sanofi by 952.6% in the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock valued at $28,000 after purchasing an additional 543 shares during the period. Finally, Sunbelt Securities Inc. raised its position in Sanofi by 72.1% in the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock valued at $43,000 after purchasing an additional 313 shares during the period. 14.04% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on SNY shares. Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Finally, StockNews.com downgraded Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Two equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $60.00.

Sanofi Stock Down 0.6 %

NASDAQ:SNY opened at $53.60 on Thursday. The company has a market capitalization of $136.03 billion, a price-to-earnings ratio of 21.53, a price-to-earnings-growth ratio of 1.01 and a beta of 0.57. Sanofi has a one year low of $45.22 and a one year high of $58.97. The stock has a 50-day simple moving average of $50.65 and a 200 day simple moving average of $52.49. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting analysts’ consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Sell-side analysts predict that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.